midodrine has been researched along with Diabetic Neuropathies in 4 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The hypothesis of ephaptic transmission was supported by meaningful decrease of muscle sympathetic activity detected by microneurography before and after the dosage of L-DOPS, which effectively suppressed the pain as well as other alpha-stimulant, midodrine hydrochloride." | 2.40 | [Pain caused by ephaptic transmission occurring in the recovery phase of diabetic vascular mononeuropathy was effectively suppressed with L-threo-3,4-dihydroxyphenyl-serine]. ( Inoue, K; Kunimoto, M; Ohshima, F, 1998) |
| " These preliminary results suggest that midodrine is safe and effective in transplant recipients; however, the dosage should be titrated to symptomatic relief or a maximum dose of 30 mg." | 1.31 | Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension. ( Alloway, RR; Gaber, AO; Hurst, GC; Somerville, KT; Stratta, RJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maule, S | 1 |
| Tredici, M | 1 |
| Dematteis, A | 1 |
| Matteoda, C | 1 |
| Chiandussi, L | 1 |
| Honma, K | 1 |
| Ohshima, F | 1 |
| Kunimoto, M | 1 |
| Inoue, K | 1 |
| Hurst, GC | 1 |
| Somerville, KT | 1 |
| Alloway, RR | 1 |
| Gaber, AO | 1 |
| Stratta, RJ | 1 |
2 reviews available for midodrine and Diabetic Neuropathies
| Article | Year |
|---|---|
[Diabetes mellitus and orthostatic intolerance].
Topics: Bandages; Diabetic Neuropathies; Diet, Sodium-Restricted; Exercise Therapy; Heart Rate; Humans; Male | 2005 |
[Pain caused by ephaptic transmission occurring in the recovery phase of diabetic vascular mononeuropathy was effectively suppressed with L-threo-3,4-dihydroxyphenyl-serine].
Topics: Adrenergic alpha-Agonists; Baroreflex; Diabetic Neuropathies; Droxidopa; Humans; Leg; Male; Middle A | 1998 |
2 other studies available for midodrine and Diabetic Neuropathies
| Article | Year |
|---|---|
Postprandial hypotension treated with acarbose in a patient with type 1 diabetes mellitus.
Topics: Acarbose; Adrenergic alpha-Agonists; Anti-Inflammatory Agents; Blood Pressure; Diabetes Mellitus, Ty | 2004 |
Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Blood Pressure; Creatinine; Diabetic Neuropathies; Female; Humans; | 2000 |